• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Not significant benefit for conventional aggressive surgical treatment over conservative medical treatment for the acute care of ICH [6]. Nevertheless,more than 7000 patients with ICH in the United States ever undergo traditional evacuation procedures each year [7]. Many various clinical studies in recent years all have tested the hypothesis that clot burden plays a significant role in several forms of intracranial hemorrhage, which seem to suggest that clot reduction plays an important role in limiting brain edema and additional neuronal injury, as well as in reducing the severity of neurological deficits following ICH [8-11]. Because of being attributed to the lack of validated therapeutic options for AICH, minimally invasive surgery (MIS) in the treatment of AICH has PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/744568 gained especial attention, and several differrent operation methods emerged over the past decade. In this context, our treatment with a stereotactic technique, which we have termed the minimally invasive stereotactic 2,2,3,3-Tetrafluoropropyl N,N'-diethylcarbamimidothioate trifluoromethanesulfonate puncture therapy (MISPT), is herewith presented. MISPT is a novel operative technique for ICH, which Methyl 2-((4-nitro-1h-pyrazol-1-yl)methyl)benzoate is developed by Pro Jia of China in 1997. Although several clinical studies on MISPT in acute phase of ICH are well recognized in the past decade, the impact of MISPT in short-term and long-term on neurological function of patients who survive the acute phase is less clear. The purpose of the present study was to investigate PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/13867361 whether MISPT could maintain long-term benefit as short-term benefit and whether this method could improve ultimate outcomes bmjopen-2016-011952 in these ICH patients. Therefore we compared the long-term outcome one year after treatment obtained in a consecutive series of ICH patients treated by MISPT with the results achieved in a comparable group of patients who were treated by conventional craniotomy (CC).Methods A prospective controlled study was undertaken. All ICH patients came from in-hospital from 2005 to 2008, diagnosed as ICH according to the ICH criteria of which is drafted by ASA [12]. The clinical trial was in compliance with the WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects, and was performed with the approval of our hospital ethics committee (Reference number: JSCS2005058). We generated the sequence for enrolling a subject and allocating the treatment by a randomized number generated by computer. All cases have been monitored in a dedicated stroke unit. Volume of the ICH in milliliters was estimated on the basis of approximate ellipse volume with the A ?B ?C/2 formula, where A represents the largest diameter of the hematoma on axial CT cuts in centimeters, B the diameter of hematoma perpendicular to A on the same cut, and C the number of CT slices in which hematoma is visible multiplied by the slice thickness in centimeters [13,14].Inclusion and exclusion criteria for patients Inclusion criteria were as follows(1) diagnosed as having spontaneous hemorrhage in the basal ganglion or brain lobe of the brain by CT scan; (2) hemorrhage volume: 30?00 ml; (3) age range: 40?5 years; (4) muscle strength of the paralyzed limbs: grades 0? on the muscle strength scale; (5) hemorrhagic duration (from stroke onset to hospital) within 24 h; (6) informed consent from patients and/or their law representative.Exclusion criteria were as follows(1) disturbances of blood coagulation, such as thrombocytopenia, hepatitis, etc.; (2) traumatic intracranial hemorrhage; (3) intracranial or general infection; (4) complica.